Related by context. All words. (Click for frequent words.) 69 Meets Primary Endpoint 68 vapreotide acetate 68 Phase 2b Clinical Trial 68 Mycophenolate Mofetil 68 Phase 2b Trial 67 Phase IIb Trial 67 Prospective Randomized 67 Antithrombin 67 Oral Fingolimod 67 Phase III Clinical Trial 67 Acute Ischemic Stroke 67 Phase 2a Clinical Trial 67 Dose Ranging Study 66 Aflibercept 66 SYN# 66 Immunotherapeutic 66 Novel Oral 66 fosbretabulin 66 Phase 2a Trial 66 Receives Orphan Drug Designation 66 Urocortin 2 66 Safinamide 66 Initiates Clinical Trial 66 Prolongs Survival 66 Initiates Clinical 66 acute peripheral arterial 66 Peripheral Arterial 66 Tezampanel 66 Dendritic Cells 66 Phase #b/#a clinical 65 somatostatin analog 65 Completes Patient Enrollment 65 Phase Ib Clinical Trial 65 Randomized Evaluation 65 Diabetic Foot Ulcer 65 Refractory Angina 65 Phase 2b Study 65 chronic thromboembolic pulmonary 65 Study Evaluating 65 Embolic Protection 65 Initiates Enrollment 65 liposomal formulation 65 Drug Candidate 65 TLK# 65 Phase III Trial 65 See CLINICAL PHARMACOLOGY 65 Randomized Double blind 65 transcranial Doppler ultrasound 65 multicenter Phase II 65 Plaque Psoriasis 65 Diabetic Neuropathy 65 Alexza Staccato 64 Achieves Primary Endpoint 64 uricase 64 vinorelbine tartrate 64 Orally administered 64 Single Dose 64 Technosphere ® 64 Clinical Trial Evaluating 64 Investigational Treatment 64 mertansine 64 Myelodysplastic Syndrome MDS 64 FOLOTYN ® 64 beta 1a 64 Pegylated Liposomal Doxorubicin 64 Pivotal Phase III 64 FDA APPROVES 64 Transdermal Patch 64 Pulmonary Arterial Hypertension 64 Tumor Response 64 Controlled Study 64 NDA Submission 64 Phase IIa Clinical Trial 64 Mg Usa 64 Severe Sepsis 64 epoetin alpha 64 intravesical infusion therapy 64 verteporfin 64 Clinical Outcome 64 thetreatment 64 Clinical Trial Results 64 Pivotal Trial 64 Diabetic Macular Edema DME 64 Demonstrates Significant 64 Zorbtive TM 64 topically administered 64 complement inhibitor eculizumab 64 Fondaparinux 64 orally inhaled 64 Natalizumab 64 Degarelix 64 Adjuvant Treatment 64 Initiate Clinical Trial 64 Intravitreal 64 pharmacokinetic PK study 63 metastatic malignant 63 PRIALT 63 HDAC Inhibitor 63 Aurora Kinase 63 Hormone Refractory Prostate Cancer 63 Shows Promise Against 63 Pivotal Clinical Trial 63 Kinase Inhibitor 63 PKC# 63 intranasal formulation 63 Squalamine 63 Hsp# Inhibitor 63 Pemetrexed 63 Dose Escalation 63 treat benign prostatic 63 Aliskiren 63 lexidronam injection 63 Granted Orphan Drug 63 A1PI 63 GW# [003] 63 Glufosfamide 63 Lymphocytic 63 Initiate Phase 63 Phase IIA 63 Adjunctive Therapy 63 Left Ventricular 63 plasma kallikrein inhibitor 63 Pivotal Study 63 rasagiline tablets 63 Files IND 63 Teriparatide 63 BRIM2 63 Ischemic 63 liposome injection 63 kidney urologic 63 MGd 63 Randomized Phase 63 Myocardial Perfusion Imaging 63 Tyrosine Kinase Inhibitor 63 Simulect 63 Parathyroid Hormone 63 Initiated Phase 63 pioglitazone hydrochloride 63 Lupus Nephritis 63 INSPIRE Trial Phase III 63 Combination REOLYSIN R 63 GORE TAG Device 63 Recombinant Human 63 Dacogen decitabine 63 IND Filing 63 Inhalation Solution 63 selective phosphodiesterase 63 Patients Treated With 63 Telaprevir VX 63 Relapsing Multiple Sclerosis 63 intravenous tissue plasminogen 62 5 Fluorouracil 62 Infarct 62 Randomized Phase II 62 Cytochrome P# 62 Pafuramidine 62 evaluating tivozanib 62 relapsed MM 62 Phase IIb clinical trials 62 Bosutinib 62 Placebo Controlled Trial 62 Disease Modifying 62 Betaferon R 62 orally inhaled migraine 62 Decitabine 62 Biolimus A9 62 BARACLUDE R 62 pioglitazone HCl 62 PLX STROKE targeting 62 memantine HCl 62 SUTENT ® 62 Enzastaurin 62 Temsirolimus 62 aurora kinase 62 docetaxel Taxotere ® 62 Phase Ib II 62 Ziprasidone 62 Controlled Trial 62 Cardiotoxicity 62 Antiviral Therapy 62 Alteplase 62 dual endothelin receptor antagonist 62 NAVISTAR R 62 PROTEGE 62 Kamada AAT 62 Pegloticase 62 Bosentan 62 OncoVex 62 CIMZIA TM 62 Inflammatory Arthritis 62 reslizumab 62 Initiates Clinical Trials 62 LymphoStat B TM 62 Antitumor Activity 62 Chronic Heart Failure 62 CRMD# 62 lucinactant 62 Preclinical Study 62 induced macular edema 62 icatibant 62 PD LID 62 PEG IFN 62 SNT-MC#/idebenone 62 BrachySil TM 62 MAGE A3 ASCI 62 RE LY ® 62 RhuDex 62 Romiplostim 62 Deferiprone 62 humanized interleukin 6 62 Antiplatelet 62 peripherally acting 62 Adult Stem Cell Therapy 62 Autologous Stem Cell Transplantation 62 intradermal injections 62 Fulvestrant 62 Cimzia ® certolizumab pegol 62 Phase 1a clinical 62 PHX# 62 TRO# 62 interferon gamma 1b 62 Phase III multicenter 62 SPRYCEL ® 62 Factor VIIa 62 YONDELIS 62 Late Breaker 62 recombinant tissue plasminogen 62 HDL Selective Delipidation 62 Randomized Study 62 STRIDE PD 62 ECASS 62 Schizophrenia Treatment 62 ACOMPLIA R 62 Neupogen ® 62 CALGB # [002] 62 cromolyn sodium 62 toenail onychomycosis 62 VentiRx Pharmaceuticals 62 Advanced Renal Cell 61 J Am Coll 61 Adjuvant Therapy 61 Acute Coronary Syndromes 61 zoledronate 61 Sirolimus eluting Coronary Stent 61 FDA Approvals 61 Dupuytren Contracture 61 Advanced Melanoma 61 IND Application 61 Enzyme Replacement Therapy 61 r hGH 61 Intravascular 61 Ranolazine 61 mGluR2 NAM 61 reteplase 61 Val HeFT 61 Quinamed 61 Cardiac Resynchronization Therapy 61 Spiegelmer ® 61 DURIN TM 61 potent suppressor 61 Vicriviroc 61 pregabalin Lyrica 61 CYP#A# CYP#D# 61 visilizumab 61 Oral Insulin 61 rt PA 61 Randomized Double Blind Placebo 61 cardio renal 61 ORENCIA ® 61 insulin glulisine 61 Zenvia Phase III 61 Epratuzumab 61 LAB CGRP 61 protein tyrosine phosphatase 1B 61 CTAP# Capsules 61 Randomized Double Blind 61 Nerve Targeting Drug 61 Newly Diagnosed Multiple Myeloma 61 levodopa induced dyskinesia 61 Insulin Nasal Spray 61 Febuxostat 61 alfa 2a 61 deCODE AF TM 61 Intranasal 61 Bare Metal Stent 61 Ticagrelor 61 Trandolapril 61 Percutaneous Tibial Nerve Stimulation 61 RhuDex ® 61 Bayer HealthCare Onyx Pharmaceuticals 61 AZILECT ® 61 Bazedoxifene 61 Improves Outcomes 61 Glypromate 61 Levoleucovorin 61 Metabolic Disorder 61 DermaVir Patch 61 Risk Stratification 61 PRT# 61 Acute Decompensated Heart Failure 61 brand ciclesonide HFA 61 Benign Prostatic Hyperplasia 61 Serostim ® 61 CHAMPION PCI 61 Cardiometabolic 61 Angiox ® 61 Submits NDA 61 Anavex #-# 61 GRNCM1 61 phase IIb study 61 ACTOS ® 61 sunitinib Sutent 61 Patients Receiving 61 milrinone 61 Cypher Sirolimus 61 Telithromycin 61 Intervention Effectiveness 61 Ketotransdel 61 investigational antiplatelet 61 Treating Chronic 61 Androxal TM 61 Phase Ib IIa 61 Dabigatran etexilate 61 recurrent glioblastoma multiforme 61 Completes Enrollment 61 Renal Cancer 61 Randomized Clinical Trial 61 Renal Impairment 61 ZOLINZA 61 Improves Survival 61 Sutent sunitinib malate 61 Pharmacokinetic Study 61 ® pioglitazone HCl 61 Fabry Disease 61 Adjuvant Chemotherapy 61 Viprinex TM 60 Demonstrates Efficacy 60 lenalidomide Revlimid R 60 Relapsed Multiple Myeloma 60 #-# Full Text 60 ThermoDox R 60 FUSILEV enhances 60 sulodexide 60 Pooled Analysis 60 E1 INT TM 60 Atomoxetine 60 clevidipine 60 VAPRISOL 60 ABLYNX 60 Patency 60 Deforolimus 60 Teva Provides Update 60 Placebo Controlled Study 60 Guanilib 60 Antiangiogenic 60 IIb clinical trial 60 azilsartan medoxomil 60 bortezomib Velcade 60 Azacitidine 60 apomorphine hydrochloride 60 Trobalt 60 Radiofrequency Ablation 60 ancrod 60 Acute Treatment 60 Sevelamer 60 Selective Cardiac Myosin Activator 60 Innate Immune 60 Montelukast 60 Lung Cancer Trial 60 Phase IIB 60 Diabetic Nephropathy 60 Dalbavancin 60 TO AVOID PREGNANCY WHILE 60 selective adenosine 60 humanised monoclonal antibody 60 ischemia induced 60 Int J Obes Relat 60 Tasigna prolongs 60 Phase IIIb clinical 60 Myoblast 60 TBC# 60 Safety Tolerability 60 Phase Ib study 60 Archexin 60 Maleate 60 patientswith 60 Double Blind Placebo 60 Treated Patients 60 Elagolix 60 SNT MC# 60 oral salmon calcitonin 60 selective A1 adenosine 60 J Am Acad 60 Cardiomyocytes 60 #/#mg 60 multicenter phase 60 Naive Patients 60 CIMZIA TM certolizumab pegol 60 LUMINATE 60 Novel Antibiotic 60 Left Ventricular Dysfunction 60 cardiac repolarization 60 PYY #-# 60 Catheter Ablation 60 CardioFit 60 Promedior 60 pain palliation 60 HuMax 60 Transdermal Delivery 60 Mg Uk 60 IN PATIENTS WITH 60 Systemic Sclerosis 60 Patient Enrolment 60 ANN INTERN MED 60 R lenalidomide 60 Tarceva TM 60 novel oral anticoagulant 60 Denufosol 60 abacavir Ziagen 60 sodium thiosulfate STS 60 plus DOXIL 60 Unfractionated Heparin 60 Ramelteon 60 Neupro R 60 Non Alcoholic Steatohepatitis 60 PEGINTRON TM 60 PresbyLens ® 60 leukotriene pathway 60 assessing T DM1 60 Immunomedics Announces 60 Captopril 60 Confirmatory Phase 60 GAMMAGARD 60 Catena ® 60 Adjunctive 60 Is Well Tolerated 60 Interferon Gamma 60 Acute Heart Failure 60 Vernakalant 60 Randomized Clinical Trials 60 Clinical Trial Data 60 TRA 2P 60 Glatiramer Acetate 60 non valvular atrial 60 Kahalalide F 60 PressureWire 60 Hydroxyurea 60 Aztreonam 60 MEND CABG II 60 Files Investigational 60 Dual Antiplatelet Therapy 60 doi #.#/fj.#-# 60 trastuzumab DM1 T DM1 60 Tissue Plasminogen Activator 60 Cand5 60 Proellex TM 60 Renal Insufficiency 60 LymphoStat B belimumab 60 HuMax EGFr 60 Confirms Efficacy 60 Interferon beta 1b 60 Prospective Multicenter 60 oral transmucosal 60 Slows Progression 60 generation purine nucleoside 60 terlipressin 60 Soliris eculizumab 60 RECORD1 60 Galantamine 60 Pirfenidone 60 Nipent R 60 biliary tract cancer 60 vincristine doxorubicin 60 chimeric monoclonal antibody 60 Valsartan 60 Intravenous immunoglobulin 60 Complicated Skin 60 Hematological Malignancies 60 factor Xa inhibitor 60 Antiviral Activity 60 liposomal doxorubicin 60 OHR/AVR# 60 Mestinon 60 riociguat 60 metastatic castration resistant 60 Magnetic Stimulation 60 Aloxi injection 60 Phase 2a Study 60 BrachySil ™ 60 Poster Discussion 60 salmeterol fluticasone 60 Microalbuminuria 60 Wellmune WGP 60 Panzem NCD 60 eFlow R 60 investigational oral inhibitor 60 Panzem ® 60 Announces Poster Presentations 60 clot retrieval 60 Ambrisentan 60 Phase Ib clinical 60 AA Amyloidosis 60 Ferinject R 60 Thrombolysis 60 Predict Risk 60 intravenously administered 59 NeuroSTAT ® 59 oral anti arrhythmic 59 NSABP B 59 MVax 59 ara C 59 Pharmacokinetics PK 59 beta2 agonist 59 Combination Treatment 59 EGFR HER2 59 Demonstrate Significant 59 Carotid 59 candesartan cilexetil 59 Chemotherapy Induced 59 HYCAMTIN 59 Raptiva R 59 MelaFind R 59 mitoxantrone plus 59 NV1FGF 59 J Allergy Clin 59 Treatment Naïve 59 Current Controlled Trials 59 Crit Rev 59 buccal spray 59 Trodusquemine 59 Fractional Flow Reserve 59 thalidomide Thalomid 59 CHARISMA trial 59 vaso occlusive crisis 59 Stent Thrombosis 59 subcutaneous immunoglobulin 59 mechanical thrombectomy 59 Protease Inhibitor 59 Hepatocellular Carcinoma 59 busulfan 59 Seasonal Influenza Vaccine 59 TM Drug Eluting 59 Aggressive Reduction 59 Interferon Beta 59 vecuronium 59 Progressive Multifocal Leukoencephalopathy 59 Prospective Randomized Trial 59 Metastatic Prostate Cancer 59 vitro cytotoxicity 59 BCR ABL inhibitor 59 retinal vein occlusion induced 59 Alair System 59 Divalproex Sodium 59 HepaGam B TM 59 chills fever headache 59 Multiple Ascending Dose 59 phase IIa clinical 59 Rilonacept 59 Cardioxyl Pharmaceuticals 59 Desmoteplase 59 PICSO ® 59 Cilostazol 59 Embolic Protection Device 59 NP2 Enkephalin 59 Ondansetron Injection USP 59 Moxifloxacin 59 Fingolimod 59 anti Parkinsonian 59 omacetaxine mepesuccinate 59 Silodosin 59 Shows Efficacy 59 Demonstrates Sustained 59 Inosine 59 rFVIIa 59 novel immunotherapeutic 59 Overactive Bladder 59 Bicalutamide 59 cisplatin gemcitabine 59 Diastolic Heart Failure 59 Well Tolerated 59 Selective Cardiac Myosin 59 Biphasic 59 TORISEL TM 59 Gastric Cancer 59 Phase III ADT 59 rxRNA 59 Lung Cancer Drug 59 colesevelam HCl 59 Sandostatin R 59 Double Blind Randomized 59 biologic DMARD 59 Perforomist ™ Inhalation Solution 59 CLARITY TIMI 59 Bevasiranib 59 A2 Lp PLA2 59 OncoGel 59 Orally Active 59 estramustine 59 Anticancer Drug 59 Nicotine Vaccine 59 Improve Survival 59 Trofex 59 TASKi3 59 imexon 59 Phase IIb III 59 Proc Am Soc 59 Serdolect ® 59 HCV Protease Inhibitor 59 eprotirome 59 glycoprotein IIb IIIa inhibitor 59 Remission Maintenance 59 SCIB1 59 symptomatic intracranial 59 Intracoronary 59 Pertuzumab 59 Multiple Myeloma MM 59 Kinoid 59 Myeloma Patients 59 Edoxaban 59 Amgen Neulasta R 59 nucleotide analogue 59 Optical Coherence Tomography 59 Valopicitabine 59 reduce serum phosphate 59 Octreolin 59 EMSAM 59 Alvesco R 59 Phase III Clinical Trials 59 AZILECT R 59 Acute Myocardial Infarction 59 briakinumab 59 intranasal delivery 59 prospective multicenter randomized 59 Tiotropium 59 Xelox 59 Posaconazole 59 cinacalcet 59 NTx 59 aspirin clopidogrel 59 Teriflunomide 59 phase IIb clinical 59 Metastatic Renal Cell Carcinoma 59 Pemphigus Vulgaris 59 heFH 59 Chronic Hepatitis C 59 Etanercept 59 RAPTIVA 59 Reduces Mortality 59 EINSTEIN DVT 59 Cimzia TM 59 Nonalcoholic Steatohepatitis 59 Slow Progression 59 Renal Cell Carcinoma RCC 59 Rigel R# 59 Bronchodilator 59 vidofludimus 59 Phase 1b clinical trials 59 Demonstrates Positive 59 aripiprazole Abilify 59 Collategene 59 ENESTnd 59 Anti CD# Antibody 59 Prosaptide 59 Long Term Efficacy 59 Thrombolytic 59 ergot derivatives 59 dissolving clots 59 Carotid Revascularization Endarterectomy vs. 59 Chronic Sinusitis 59 Abrupt discontinuation 59 ASTEROID 59 Onconase 59 Embolic Protection System 59 LEUKINE 59 8mg/kg 59 Randomised 59 MEVACOR 59 multicenter randomized placebo controlled 59 ZFP TF 59 Interferon beta 1a 59 Angiotensin II 59 AIR2 Trial 59 EP #R 59 refractory chronic lymphocytic 59 multicenter Phase III 59 Abstract Number 59 oral FTY# 58 Altera Nebulizer System 58 lutropin alfa 58 Hematopoietic 58 Multicenter Study 58 Therapy Evaluation 58 experimental allergic encephalomyelitis 58 Regeneron Pharma 58 Ischemic Stroke 58 alteplase 58 randomized Phase IIb 58 metaglidasen 58 Tipranavir 58 Cancer Incidence Mortality 58 erlotinib Tarceva ® 58 Randomized Phase III 58 IMPACT DCM 58 VNP#M 58 FDG PET imaging 58 Carbidopa Levodopa 58 phase Ib 58 NYHA Class II 58 miconazole Lauriad ® 58 Captisol Enabled 58 DP b# 58 Drug Eluting 58 Vidaza azacitidine 58 QuadraSphere 58 MEND CABG 58 ThermoDox ® clinical 58 Vaccine Adjuvants 58 prasugrel Effient 58 Syncria R 58 EDEMA3 trial 58 Pyridorin 58 pentostatin 58 PHASE III 58 Arch Neurol 58 NOX E# 58 prospective multicenter study 58 Sipuleucel T 58 Tramiprosate ALZHEMED TM 58 See WARNINGS 58 brivanib 58 ON #.Na 58 Catheter Associated 58 BEZ# 58 Shows Promising 58 HFA MDI 58 Hycamtin ® 58 Keryx Biopharma 58 REVEAL Registry 58 Neovasc Reducer 58 Nuron Biotech 58 Rheos System 58 Angiogenic 58 Lung Injury 58 Androgel R 58 Gout Drug 58 Diamyd r 58 cis retinoic acid 58 advanced hepatocellular carcinoma 58 biologic antibody 58 DCCR 58 vaccine ChronVac C 58 intra articular injection 58 Activase 58 Efficacy Results 58 Myelodysplastic Syndromes 58 NATRECOR ® 58 CD# monoclonal antibody 58 Unstable Angina 58 humanized therapeutic 58 J Clin 58 number NCT# ClinicalTrials.gov 58 Chronic Hepatitis B 58 Initiate Phase II 58 CorVue ™ 58 plasmid encoding 58 Heart Failure Patients 58 cathepsin K inhibitor 58 pyridostigmine 58 drotrecogin alfa activated 58 Fungal Infections 58 Oral Session 58 Conjugate 58 relapsing remitting MS RRMS 58 Soft Tissue Sarcoma 58 Trophos 58 Iron Overload 58 Ischemia 58 Brain Metastases 58 TransPharma 58 Beta catenin pathway 58 TREDAPTIVE 58 SIMCOR 58 Immunosuppressant 58 intravenous bolus 58 Phase III confirmatory 58 Announcement acc 58 Biomarker Study 58 Nesiritide 58 J Antimicrob Chemother 58 Lp PLA 2 58 SABCS 58 etanercept Enbrel 58 NLTX 58 Monotherapy 58 abstr 58 Aplidin R 58 Fibrinogen 58 steroid refractory ulcerative 58 Thromboembolism 58 platelet dysfunction 58 Relapsing Remitting Multiple Sclerosis 58 trodusquemine 58 mecamylamine 58 vitro pharmacology 58 Virtual Histology 58 ZFP Therapeutics 58 Survival Benefit 58 Monoclonal antibody 58 rocuronium bromide 58 Vitaxin 58 Oxytrol R 58 ELACYT 58 #:#-# [031] 58 doxorubicin Transdrug ® 58 pyrazinamide 58 Excretion 58 Orthop Surg 58 phase IIa 58 GOUT 58 Sirolimus eluting 58 unfractionated heparin UFH 58 Neoadjuvant 58 denileukin diftitox 58 recombinant factor VIIa 58 Lenalidomide 58 Prognostic Significance 58 5 HT3 antagonist 58 SPP# Rasilez 58 reuptake inhibitor 58 J Nutr 58 TMS Therapy 58 Chemoradiation 58 RE MODEL 58 Clinical Efficacy 58 coronary stent merged 58 cytochrome p# 58 Castration Resistant Prostate Cancer 58 Litx 58 endothelin antagonist 58 anticholinergic agents 58 Glybera 58 rufinamide 58 Anticancer Drugs 58 Xcellerated T Cells 58 Microwave Ablation System 58 saphenous vein graft 58 hepatocellular carcinoma liver 58 systemic hypotension 58 Acute Liver Failure 58 solithromycin 58 Intravenous Formulation 58 Zarnestra 58 Obstet Gynecol 58 MERLIN TIMI 58 EndoTAG TM -1 58 ALVESCO R 58 OZURDEX 58 Nonclinical 58 Intracerebral Hemorrhage 58 Anticonvulsant 58 SYGNIS 58 mediated inhibition 58 LEVADEX ™ 58 cardiac resynchronisation therapy 58 PD2i 58 VESTASYNC 58 NTDDS 58 ADVANCE PD 58 Glybera R 58 Patient Registry 58 FDA Okays 58 Dose Ranging 58 Breast Cancer Assay 58 Desvenlafaxine Succinate 57 Chrysalin 57 agalsidase alfa 57 Topline Results 57 Rheumatoid Arthritis Patients 57 HuMax TAC 57 Peginterferon 57 XTEN 57 CNS Disorders 57 CINQUIL 57 Neoadjuvant Chemotherapy 57 acting inhaled anticholinergic 57 PI3K/Akt pathway inhibitor 57 Nephrol Dial Transplant 57 Systemic Lupus Erythematosus 57 XYOTAX TM 57 daily subcutaneous injections 57 Renal Function 57 Patients Undergoing 57 APEX PD 57 pharmacokinetic PK 57 platelet aggregation inhibitor 57 Curr Opin 57 Sprycel dasatinib 57 blinded randomized placebo controlled 57 achieved CCyR 57 alemtuzumab Campath 57 cardiac contractility 57 Drug Shows Promise 57 Cell Transplant 57 fludarabine cyclophosphamide 57 Multicenter 57 gemtuzumab ozogamicin 57 Relapsed Refractory 57 Truvada tablets 57 BioSTAR ® 57 bosentan Tracleer 57 Sleep Disturbances 57 Bipolar Depression 57 Therapeutic Competitors companiesandmarkets.com adEgemonye 57 Interferon Alfa 57 weekly subcutaneous injections 57 biased ligand 57 pancrelipase 57 gallium nitrate 57 Symptom Relief 57 inhaled AAT 57 Therapeutic Targets 57 Treat Anemia 57 REMINYL ® 57 Therapeutic Vaccine 57 Phase III psoriasis 57 Oral Presentation 57 Tanespimycin 57 CA9 SCAN 57 antiangiogenic therapy 57 #mg #mg #mg [003] 57 HeartNet 57 Coronary Angiography 57 Tyrima 57 certolizumab 57 Interferon beta 57 FASEB J. 57 HepaSphere 57 Sifrol ® 57 Subgroup Analysis 57 valproate sodium 57 Amgen Nplate 57 Retisert 57 EVEREST II 57 modified REGENESIS Phase IIb 57 Portal Hypertension 57 SIR Spheres 57 evaluating Actimmune 57 novel synthetic peptide 57 administered intranasally 57 bi ventricular pacing 57 Myocardial Infarction 57 Viprinex 57 Allogeneic 57 short acting bronchodilator 57 Stent Restenosis 57 noninvasive outpatient 57 Rotavirus Vaccine 57 PSN# [001] 57 Acute Coronary Syndromes ACS 57 Fentanyl Taifun 57 Darapladib 57 Brentuximab Vedotin SGN 57 Aerosurf 57 Paliperidone 57 inotropic 57 SoftScan ® 57 Acute Stroke 57 ALN VSP Phase 57 PROCRIT ® 57 Adenoscan 57 THERAPEUTICS 57 histamine dihydrochloride 57 EOquin TM 57 brivaracetam 57 GSK# [001] 57 COPERNICUS 57 MBRX 57 Vascugel ® 57 Cholesterol Lowering Drug 57 LT NS# 57 BZA CE 57 chemotherapeutic regimen 57 Pradaxa ® 57 Treatment Regimen 57 dihydroergotamine 57 Coronary Artery Bypass Graft 57 phase IIb III 57 Subgroup analysis 57 erlotinib Tarceva 57 Diamondback #deg 57 Glatiramer acetate 57 Carvedilol 57 COSTAR II 57 bolus injection 57 ZD# [001] 57 Antihypertensive 57 Immunosuppression 57 Therapy Improves 57 Inflammatory Markers